Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Senseonics Holdings, Inc. (NYSE American: SENS) has announced equity grants to 17 new employees under its 2019 Inducement Plan. On April 1, 2022, the Compensation Committee granted non-qualified stock options for an aggregate of 142,000 shares at an exercise price of $1.94, reflecting the closing stock price on that date. The options will vest over four years, contingent on the employees' continued service. Senseonics aims to expand its Eversense CGM System to more diabetes patients in the U.S. and globally, enhancing their product offerings.
Senseonics Holdings, Inc. (SENS) reported its financial results for Q4 and the full year 2021. The fourth quarter total revenue reached $4.0 million, a slight increase from $3.9 million in Q4 2020. The significant net income of $84.4 million contrasts sharply with a net loss of $101.6 million in Q4 2020. Full-year revenue surged to $13.7 million, up from $4.9 million in 2020, driven by post-Covid sales and the transition of Eversense commercialization to Ascensia. Looking forward, the 2022 global revenue outlook is estimated between $14.0 million and $18.0 million.
Senseonics Holdings, Inc. (AMEX: SENS) will release its fourth quarter and full year 2021 financial results on March 1, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss performance details. Investors can access the call by dialing specific numbers or through a webcast on the company’s website. Senseonics focuses on developing long-term, implantable continuous glucose monitoring (CGM) systems, with products like Eversense® and Eversense® E3 designed to enhance diabetes management.
Ascensia Diabetes Care announced FDA approval for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System, developed by Senseonics (NYSE American: SENS). This system boasts a sensor life of up to six months, significantly enhancing patient convenience with only two sensor insertions required annually. The E3 sensor demonstrates exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5% from the PROMISE Study. The product aims to launch in the U.S. in Q2 2022, supported by programs to improve patient access and affordability.
Senseonics Holdings, Inc. has announced FDA approval for the Eversense® E3 Continuous Glucose Monitoring (CGM) System, the only long-term implantable CGM, which provides accurate glucose monitoring for up to 6 months. This next-generation device features proprietary SBA technology and is set to be available publicly through Ascensia Diabetes Care in Q2 2022. The company projects 2022 global net revenue between $14 million and $18 million, with ongoing investment in R&D for further product development.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to attract new employees. On January 4, 2022, three non-executive employees received options for 30,000 shares at an exercise price of $2.68 per share. The options vest over four years, contingent on employment status. Senseonics continues to pursue the development and availability of its Eversense Continuous Glucose Monitoring system globally, aiming to aid those living with diabetes.
Senseonics Holdings, Inc. (NYSE American: SENS) announced updates regarding their next-generation Eversense 180-day continuous glucose monitoring (CGM) system. The FDA's review for the PMA supplement is nearing completion, with a decision expected soon. The company is working with Ascensia Diabetes Care to ensure a smooth transition to the new system, including marketing campaigns and reimbursement plans. Senseonics maintains its revenue outlook for 2021, projecting net revenues between $12 million and $15 million.
Senseonics Holdings, Inc. (SENS) announced the receipt of the CE mark for its Eversense NOW Remote Monitoring App for Android, enhancing its long-term continuous glucose monitoring system. The app, which offers real-time glucose data monitoring for users and their families, is expected to launch in Q1 2022. The Eversense XL CGM System allows glucose measurement for up to 180 days. The company emphasizes its commitment to transforming diabetes management with innovative technology.
Senseonics Holdings, Inc. (SENS) reported third quarter 2021 revenue of $3.5 million, a significant increase from $0.8 million in Q3 2020. U.S. revenue was $0.6 million, while international sales reached $2.9 million. The net income surged to $42.9 million or $0.10 per share, a turnaround from a net loss of $23.4 million a year prior. However, the company anticipates 2021 global net revenue to fall within $12 million to $15 million due to uncertainties related to COVID-19 and FDA reviews.
Senseonics Holdings, Inc. (AMEX: SENS) has announced participation in two upcoming investor conferences. Management will engage in a virtual fireside chat on November 16, 2021, at 8:40am ET during the Stifel 2021 Virtual Healthcare Conference. Additionally, a presentation will be available on November 18, 2021, at 3:00am ET at the Jefferies London Healthcare Conference. Interested parties can access live and on-demand webcasts on the Company’s website. Senseonics focuses on long-term glucose monitoring systems for diabetes management.